New Delhi-based Parijat Industries (India) Ltd has filed its Draft Red Herring Prospectus (DRHP) with capital markets regulator, Securities and Exchange Board of India (SEBI) for its Initial Public Offering (IPO).

The offer, with a face value of Rs 5, is a fresh issue aggregating up to Rs 160 crore and an offer for sale of 20, 370, 680 shares.

The offer also includes a subscription reservation by eligible employees, and a discount is being offered to eligible employees bidding in the employee reservation portion.

The proceeds from its fresh issuance worth Rs 121.6 crore will be utilized for repayment/pre-payment, in full or part of certain borrowings availed by the company including payment of accrued interest thereon, and general corporate purposes.

The Offer is being made through the book-building process, wherein not more than 50% of the net offer is allocated to qualified institutional buyers, and not more than 15% and 35% of the net offer is assigned to non-institutional bidders and retail individual bidders respectively.


The company is an India-headquartered agrochemical company with a multinational presence and a focus on innovation, product development and distribution of branded formulations. The company is engaged in the development, manufacture and distribution of agrochemicals, under the following categories – formulations, consisting of plant protection products, sub-categorized under insecticides, fungicides, bactericides, herbicides, and combinations thereof, and plant nutrition products (other than chemical fertilizers) comprising specialty fertilizers, bio-stimulants and plant growth regulators (PGRs) and technical grade active ingredients (Technicals), which are utilized in the manufacture of agrochemical formulations.

As of March 31, 2025, its global presence spanned to 65 countries across Asia, West Africa, Europe and North America. The company’s domestic business complements its international business.

Domestic business: In its domestic business, for which it holds 283 registrations as of August 31, 2025, comprises domestic branded sales, under which it distributes a portfolio of plant protection and plant nutrition products marketed under 90 brands across 20 states in India. In relation to this portfolio, the company also holds 10 product patents as of the date of this Draft Red Herring Prospectus, and domestic corporate sales, wherein it undertakes the sale of Technicals and finished formulations (on a bulk basis) to corporate customers, and also co-market its proprietary formulations through its other brand players in ready-to-market packaging under their own brands.

And during Financial Year 2025, its domestic corporate customers included Mankind Agritech Private Limited, Rallis India Limited, IFFCO MC Crop Science Private Limited, Coromandel International Limited, Bayer Cropscience Limited and Dhanuka Agritech Limited.

International business: Its international business focuses on the export of its branded formulations, primarily to markets where the registration process for agrochemicals is lengthy and complex. Its key markets like West Africa, Russia and North America have stringent or lengthy regulatory approval processes (as per the CRISIL Report), thus creating entry barriers for new players. As of August 31, 2025, the company holds 512 product registrations across overseas jurisdictions. The company undertakes its international business through different go-to-market strategies.

The company is the first Indian company to obtain technical import registration for products such as Fipronil, Pyriproxyfen, Chlorfenapyr, Imazamox and Kresoxim methyl, and to obtain technical indigenous manufacture registrations for Mesotrione and Metamifop for the Indian market, thereby reinforcing our early mover advantage.

The company has continued to expand its domestic branded formulations portfolio and deepen its market penetration across India where it operates across 20 states through its network of 5,433 dealers, distributers, wholesalers and retailers who are its direct customers as of March 31, 2025. And simultaneously the company is expanding its global presence across 65 countries pursuant to direct relationships with overseas customers, and through seven foreign subsidiaries in overseas markets, , Belin Russia in Russia, Leeds Lifescience Limited in UK, Parijat Tanzania Limited in Tanzania, Parijat Mali S.A in Mali Belin International Limited in Hong Kong, and Parijat Togo in Togo.

The company operates a Technicals manufacturing facility situated in Cuddalore, Tamil Nadu, India through its subsidiary, Crimsun Organics Private Limited, at which it manufactures some key Technicals, including Fipronil, Dinotefuran, Pyriproxifen, Fluroxapyr, Metamifop, Oxadiargyl, Pyrithiobac Sodium and Mesotrione, which are primarily supplied to its formulation units for use in manufacture of formulations.

Further, the company is the process of acquiring Saykha, Gujarat wherein it proposes to set up an additional manufacturing facility for Technicals. The company is also engaged with third party manufacturers at sites to supplement its Technicals manufacturing capabilities through job-working arrangements, using its processes and intermediates, at external sites.

The company currently develops and manufactures its formulation products in India primarily at three manufacturing units – two located in Ambala, Haryana, and one in Vadodara, Gujarat.

In addition, the company operates a formulations manufacturing unit in Ambala, Haryana, through its subsidiary, Leeds Life Sciences Private Limited.

As on the date of this Draft Red Herring Prospectus, the company has seven in-house research and development (“R&D”) laboratories in India to complement its manufacturing capabilities. And approximately two decades of manufacturing experience, coupled with its significant product development capabilities with a focus on developing proprietary formulations, has resulted in 10 product patents granted in India and 10 product patents granted overseas as of August 31, 2025.

Further, the company has 15 patent applications pending in India and 19 patent applications pending internationally, as of August 31, 2025. Further, the company also has two process patent applications for Technicals manufacturing pending as of August 31, 2025.

The company’s revenue from operations was Rs 1045.3 crore during FY25 vis-à-vis Rs 1028.5 crore during FY23. Its net profit was Rs 54 crore during FY25 vis-à-vis Rs 42.4 crore during FY23.

SBI Capital Markets and Ambit Private Limited are the book-running lead managers and KFin Technologies Limited is the registrar of the offer.